Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03501381 · ClinicalTrials.gov registry record · Phase 2

High Dose IL 2 and Entinostat in RCC

A Phase 2 study of Renal Cell Carcinoma, sponsored by Roberto Pili.

Active
Registry status
Phase 2
Development phase
46
Enrollment target
5
Study locations

NCT03501381 is a Phase 2 study of Renal Cell Carcinoma that is active but no longer recruiting, run by Roberto Pili. The registered enrollment target is 46 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03501381, a Phase 2 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Roberto Pili.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
46 participants
Enrollment target
5
Study locations

Study Summary

This is a multicenter, randomized, open label study of high dose interleukin 2 vs high dose interleukin 2 plus entinostat in clear cell RCC patients who are candidate for high dose interleukin 2. Patients will be randomized to ARM 1 (high dose interleukin 2 plus entinostat) or ARM 2 (high dose interleukin 2). Subjects will receive up to 3 courses of high dose interleukin 600,000 units/kg administered IV every 8 hrs on Days 1-5 and Days 15-19 (maximum 28 doses) +/- entinostat 5 mg orally given every 2 weeks starting on Day-14, continuously. Tumor response assessment will be performed between HD IL-2 courses.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Interleukin-2
  • DRUG Entinostat

Study Locations (5)

California

  • Univeristy of Southern California - Los Angeles

Illinois

  • Rush University Medical Center - Chicago

Indiana

  • Indiana Univeristy Melvin and Bren Simon Cancer Center - Indianapolis

Louisiana

  • Hematology Oncology Clinic, LLC - Baton Rouge

Nebraska

  • Nebraska Methodist Hospital - Omaha

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2018-05-24
Est. Completion 2024-04
Phase Phase 2

Sponsor

Roberto Pili

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03501381

The ClinicalTrials.gov registry entry for NCT03501381 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (81% lower). The listed sponsor is Roberto Pili, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Interleukin-2 is the first listed.

NCT03501381 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Indiana.

Frequently Asked Questions

What is clinical trial NCT03501381 about?

NCT03501381 is a clinical study titled "High Dose IL 2 and Entinostat in RCC". This is a multicenter, randomized, open label study of high dose interleukin 2 vs high dose interleukin 2 plus entinostat in clear cell RCC patients who are candidate for high dose interleukin 2. Patients will be randomized to ARM 1 (high dose interleukin 2 plus entinostat) or ARM 2 (high dose inter...

What is the current status of trial NCT03501381?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2018-05-24. Estimated completion is 2024-04.

What conditions does trial NCT03501381 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT03501381?

The interventions under investigation include: Interleukin-2 (DRUG), Entinostat (DRUG).

Who is sponsoring clinical trial NCT03501381?

This trial is sponsored by Roberto Pili, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03501381 being conducted?

This trial has 5 study locations across California, Illinois, Indiana, Louisiana, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.